Imunon, Inc. is a biotechnology enterprise operating at the clinical development stage, dedicated to the advancement and commercialization of innovative DNA-centric immunotherapeutic agents, vaccines, and targeted chemotherapy treatments. Its product pipeline prominently features GEN-1, a DNA-based immunotherapy specifically designed for the localized management of ovarian cancer. Alongside this, the company is developing ThermoDox, a proprietary liposomal formulation of doxorubicin that is activated by heat, currently being explored for various oncological indications. Beyond its specific product candidates, Imunon also possesses two early-stage platform technologies, which serve as foundational tools for crafting additional nucleic acid-based immunotherapies, vaccines, and diverse anti-cancer DNA or RNA therapeutics. Founded in 1982 and headquartered in Lawrenceville, New Jersey, the company was formerly recognized as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
